NAFLD in type 1 diabetes: overrated or underappreciated?

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in western countries, affecting 25–30% of the general population and up to 65% in those with obesity and/or type 2 diabetes. Accumulation of visceral adipose tissue and insulin resistance (IR) contributes to NAFLD. NAF...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jonathan Mertens, Luc F. Van Gaal, Sven M. Francque, Christophe De Block
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Diseases of the endocrine glands. Clinical endocrinology RC648-665
Acceso en línea:	https://doaj.org/article/309a074d7b7f4f34b4d8166ab91feff0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:309a074d7b7f4f34b4d8166ab91feff0
record_format	dspace
spelling	oai:doaj.org-article:309a074d7b7f4f34b4d8166ab91feff02021-11-23T23:03:25ZNAFLD in type 1 diabetes: overrated or underappreciated?2042-019610.1177/20420188211055557https://doaj.org/article/309a074d7b7f4f34b4d8166ab91feff02021-11-01T00:00:00Zhttps://doi.org/10.1177/20420188211055557https://doaj.org/toc/2042-0196Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in western countries, affecting 25–30% of the general population and up to 65% in those with obesity and/or type 2 diabetes. Accumulation of visceral adipose tissue and insulin resistance (IR) contributes to NAFLD. NAFLD is not an innocent entity as it not only may cause nonalcoholic steatohepatitis and cirrhosis but also contribute to cardiovascular morbidity and mortality. More and more people with type 1 diabetes (T1D) are becoming overweight and present with features of IR, but the prevalence and impact of NAFLD in this population are still unclear. The utility of noninvasive screening tools for NAFLD in T1D is being explored. Recent data indicate that based upon ultrasonographic criteria NAFLD is present in 27% (ranging between 19% and 31%) of adults with T1D. Magnetic resonance imaging data indicate a prevalence rate of 8.6% (ranging between 2.1% and 18.6%). There are, however, multiple factors affecting these data, ranging from study design and referral bias to discrepancies in between diagnostic modalities. Individuals with T1D have a 7-fold higher risk of cardiovascular disease (CVD) and cardiovascular mortality is the most prominent cause of death in T1D. Patients with T1D and NALFD are also more prone to develop CVD, but the independent contribution of NAFLD to cardiovascular events has to be determined in this population. Furthermore, limited data in T1D also point towards a 2 to 3 times higher risk for microvascular complications in those with NAFLD. In this article, we will discuss epidemiological and diagnostic challenges of NAFLD in T1D, explore the link between IR and NAFLD and chronic complications, and examine the independent contribution of NAFLD to the presence of macro-, and microvascular complications.Jonathan MertensLuc F. Van GaalSven M. FrancqueChristophe De BlockSAGE PublishingarticleDiseases of the endocrine glands. Clinical endocrinologyRC648-665ENTherapeutic Advances in Endocrinology and Metabolism, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the endocrine glands. Clinical endocrinology RC648-665
spellingShingle	Diseases of the endocrine glands. Clinical endocrinology RC648-665 Jonathan Mertens Luc F. Van Gaal Sven M. Francque Christophe De Block NAFLD in type 1 diabetes: overrated or underappreciated?
description	Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in western countries, affecting 25–30% of the general population and up to 65% in those with obesity and/or type 2 diabetes. Accumulation of visceral adipose tissue and insulin resistance (IR) contributes to NAFLD. NAFLD is not an innocent entity as it not only may cause nonalcoholic steatohepatitis and cirrhosis but also contribute to cardiovascular morbidity and mortality. More and more people with type 1 diabetes (T1D) are becoming overweight and present with features of IR, but the prevalence and impact of NAFLD in this population are still unclear. The utility of noninvasive screening tools for NAFLD in T1D is being explored. Recent data indicate that based upon ultrasonographic criteria NAFLD is present in 27% (ranging between 19% and 31%) of adults with T1D. Magnetic resonance imaging data indicate a prevalence rate of 8.6% (ranging between 2.1% and 18.6%). There are, however, multiple factors affecting these data, ranging from study design and referral bias to discrepancies in between diagnostic modalities. Individuals with T1D have a 7-fold higher risk of cardiovascular disease (CVD) and cardiovascular mortality is the most prominent cause of death in T1D. Patients with T1D and NALFD are also more prone to develop CVD, but the independent contribution of NAFLD to cardiovascular events has to be determined in this population. Furthermore, limited data in T1D also point towards a 2 to 3 times higher risk for microvascular complications in those with NAFLD. In this article, we will discuss epidemiological and diagnostic challenges of NAFLD in T1D, explore the link between IR and NAFLD and chronic complications, and examine the independent contribution of NAFLD to the presence of macro-, and microvascular complications.
format	article
author	Jonathan Mertens Luc F. Van Gaal Sven M. Francque Christophe De Block
author_facet	Jonathan Mertens Luc F. Van Gaal Sven M. Francque Christophe De Block
author_sort	Jonathan Mertens
title	NAFLD in type 1 diabetes: overrated or underappreciated?
title_short	NAFLD in type 1 diabetes: overrated or underappreciated?
title_full	NAFLD in type 1 diabetes: overrated or underappreciated?
title_fullStr	NAFLD in type 1 diabetes: overrated or underappreciated?
title_full_unstemmed	NAFLD in type 1 diabetes: overrated or underappreciated?
title_sort	nafld in type 1 diabetes: overrated or underappreciated?
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/309a074d7b7f4f34b4d8166ab91feff0
work_keys_str_mv	AT jonathanmertens nafldintype1diabetesoverratedorunderappreciated AT lucfvangaal nafldintype1diabetesoverratedorunderappreciated AT svenmfrancque nafldintype1diabetesoverratedorunderappreciated AT christophedeblock nafldintype1diabetesoverratedorunderappreciated
_version_	1718416084917288960

NAFLD in type 1 diabetes: overrated or underappreciated?

Ejemplares similares